Evidence map›Paper›PMID 33384430›Full record

ArticleScientific reports2020

Differences of the tumour cell glycocalyx affect binding of capsaicin-loaded chitosan nanocapsules.

Lydia von Palubitzki, Yuanyuan Wang, Stefan Hoffmann, Sabine Vidal-Y-Sy, Bernd Zobiak, Antonio V Failla, Petra Schmage, Axel John, Anayancy Osorio-Madrazo, Alexander T Bauer and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Lydia von PalubitzkiExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Yuanyuan WangExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Stefan HoffmannInstitute of Plant Biology and Biotechnology (IBBP), University of Münster, Schlossplatz 7-8, 48143, Münster, Germany.
Sabine Vidal-Y-SyExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Bernd ZobiakMicroscopy Imaging Facility, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Antonio V FaillaMicroscopy Imaging Facility, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Petra SchmageClinic of Periodontology, Preventive and Operative Dentistry, Center of Dental and Oral Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Axel JohnDepartment of Urology, University Medical Center of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Anayancy Osorio-MadrazoInstitute of Microsystems Engineering (IMTEK), Freiburg Materials Research Center (FMF), and Freiburg Center for Interactive Materials and Bioinspired Technologies (FIT), University of Freiburg, 79104, Freiburg, Germany.
Alexander T BauerExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Stefan W SchneiderExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany.
Francisco M GoycooleaSchool of Food Science and Nutrition, University of Leeds, Woodhouse Lane, Leeds, LS2 9JT, UK.
Christian GorzelannyExperimental Dermatology, Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Research Campus, Martinistraße 52, 20246, Hamburg, Germany. c.gorzelanny@uke.de.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Freiburg · DEUniversity of Leeds · GBUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The glycocalyx regulates the interaction of mammalian cells with extracellular molecules, such as cytokines. However, it is unknown to which extend the glycocalyx of distinct cancer cells control the binding and uptake of nanoparticles. In the present study, exome sequencing data of cancer patients and analysis of distinct melanoma and bladder cancer cell lines suggested differences in cancer cell-exposed glycocalyx components such as heparan sulphate. Our data indicate that glycocalyx differences affected the binding of cationic chitosan nanocapsules (Chi-NCs). The pronounced glycocalyx of bladder cancer cells enhanced the internalisation of nanoencapsulated capsaicin. Consequently, capsaicin induced apoptosis in the cancer cells, but not in the less glycosylated benign urothelial cells. Moreover, we measured counterion condensation on highly negatively charged heparan sulphate chains. Counterion condensation triggered a cooperative binding of Chi-NCs, characterised by a weak binding rate at low Chi-NC doses and a strongly increased binding rate at high Chi-NC concentrations. Our results indicate that the glycocalyx of tumour cells controls the binding and biological activity of nanoparticles. This has to be considered for the design of tumour cell directed nanocarriers to improve the delivery of cytotoxic drugs. Differential nanoparticle binding may also be useful to discriminate tumour cells from healthy cells.

Indexed as

AntipruriticsCapsaicinCell Line, TumorCell SurvivalChitosanEndothelial CellsGlycocalyxHeparan SulfateHumansNanocapsulesNeoplasmsOrgan SpecificityProtein BindingStatic ElectricityTheranostic NanomedicineAntipruriticsCapsaicinChitosanHeparan SulfateNanocapsules

Identifiers

PMID33384430
PMCPMC7775450
OpenAlexW3113749048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.